Gregory P Thill

US Patent:

20130164851, Jun 27, 2013

Filed:

Mar 25, 2011

Appl. No.:

13/636379

Inventors:

Anthony Rossomando - Cambridge MA, US
Gregory P. Thill - Cambridge MA, US
Stuart Pollard - Cambridge MA, US

Assignee:

ALNYLAM PHARMACEUTICALS, INC. - Cambridge MA

International Classification:

C12N 15/85

US Classification:

435465, 435455, 435471, 435468, 435325, 4353201, 43525411, 435419, 435358

Abstract:

Provided herein are methods and compositions for generating a cell line capable of producing a biological product, using a gene amplification based system. Methods and compositions are provided to inhibit endogenous selectable amplifiable marker genes using RNA interference and prevent the selection of false positives during generation of a custom cell line. Such methods improve efficiency of cell line development and do not require the use of specialized substrates or cells lacking the endogenous selectable amplifiable marker gene to negate the effect of endogenously expressed levels of the selectable amplifiable marker gene in cells.

US Patent:

51027895, Apr 7, 1992

Filed:

Mar 15, 1989

Appl. No.:

7/323964

Inventors:

Robert S. Siegel - San Diego CA
Richard G. Buckholz - Encinitas CA
Gregory P. Thill - San Diego CA
Lillian M. Wondrack - San Diego CA

Assignee:

The Salk Institute Biotechnology/Industrial Associates, Inc. - San Diego CA

International Classification:

C07H 1512
C12P 2100
C12P 2102

US Classification:

435 694

Abstract:

Epidermal Growth Factor (EGF) is produced by recombinant DNA technology in Pichia pastoris yeast cells.

US Patent:

58276840, Oct 27, 1998

Filed:

Apr 19, 1994

Appl. No.:

8/231342

Inventors:

Kotikanyadanam Sreekrishna - Bartlesville OK
William D. Prevatt - Bartlesville OK
Gregory P. Thill - Milton MA
Geneva R. Davis - San Diego CA
Patricia Koutz - San Diego CA
Kathryn A. Barr - Bartlesville OK
Sharon A. Hopkins - Bartlesville OK

Assignee:

Research Corporation Technologies, Inc. - Tucson AZ

International Classification:

C12N 119
C12N 1532
C12N 1563
C12N 2102

US Classification:

435 691

Abstract:

A method for producing one or more Bacillus toxin polypeptides by culturing methylotrophic yeast cells which have a gene(s) capable of expressing the Bacillus toxin polypeptide(s) in such cells under conditions that the gene(s) is/are transcribed is provided. The toxin polypeptide encoding segment of the gene(s) has a G+C content of about 40%-55%, and preferably comprises methylotrophic yeast codons. The preferred species of yeast for expressing such synthetic Bacillus toxin gene(s) is Pichia pastoris. Bacillus toxin polypeptides encoded by synthetic genes are expressed at high levels in transformed methylotrophic yeast cells. The toxin expressing cells may be administered as live cells or heat-killed whole cells to provide an insecticidal composition for killing susceptible insect larvae. Also provided by the present invention are DNAs capable of transforming methylotrophic yeast to express one or more Bacillus toxin polypeptides, cultures of such yeast cells transformed with such DNAs and novel Bacillus toxin polypeptides made by the method of the invention. The transformed yeast cells of the present invention are readily ingested as food by insect larvae which are susceptible to the toxin polypeptides.

US Patent:

57078289, Jan 13, 1998

Filed:

May 3, 1995

Appl. No.:

8/433037

Inventors:

Juerg F. Tschopp - San Diego CA
Gregory P. Thill - San Diego CA
Russell A. Brierley - San Diego CA
Kathryn A. Barr - Bartlesville OK

Assignee:

Research Corporation Technologies, Inc. - Tucson AZ

International Classification:

C12P 2106
C12N 119
C12N 1500
C12N 1563

US Classification:

435 691

Abstract:

The present invention is directed to expression cassettes comprising a 5' regulatory region from at least one of the Pichia pastoris AOXI gene, p40 gene, DASI gene or HIS4 gene, operably linked to an HSA structural gene including the HSA signal sequence. The HSA structural gene has a translational start codon within 0 to 11 deoxyribonucleotides from the 5' end of the HSA structural gene and is operably linked to a 3' termination sequence. Further, the adenine and thymine content of the intervening deoxyribonucleotides is in the range from about 55 to about 64%. The expression cassette may be an autonomously replicating vector or an integrative vector. Other embodiments of the present invention include Pichia pastoris strains transformed with the HSA expression cassettes and processes for secretion of HSA using the expression cassettes.

US Patent:

56706308, Sep 23, 1997

Filed:

Jun 6, 1995

Appl. No.:

8/467345

Inventors:

Gregory P. Thill - San Diego CA

Assignee:

Research Corporation Technologies, Inc. - Tucson AZ

International Classification:

C07K 1410
C12N 1581

US Classification:

530403

Abstract:

A process for the enhanced production of antigenic particles consisting essentially of hepatitis B S protein and preS. sub. 2 protein. Also disclosed are novel DNA molecules and hosts transformed with these molecules.

US Patent:

56502966, Jul 22, 1997

Filed:

Jun 6, 1995

Appl. No.:

8/467660

Inventors:

Gregory P. Thill - San Diego CA

Assignee:

Research Corporation Technologies, Inc. - Tucson AZ

International Classification:

C12N 119
C12N 1551
C12N 1581

US Classification:

435 693

Abstract:

A process for the enhanced production of antigenic particles consisting essentially of hepatitis B S protein and preS. sub. 2 protein. Also disclosed are novel DNA molecules and hosts transformed with these molecules.